Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
HOUSTON ― The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type,...
















